OMS906

DB17722InvestigationalProtein Based Therapies

OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.

Mechanism: Pharmacologically active on Mannan-binding lectin serine protease 1
Curator reviewed
Also known as: Humanized immunoglobulin G4 monoclonal antibody directed against mannan-binding lectin-associated serine protease-3 (MASP-3)
Code names: OMS-906

Resolves to

Compound

UNII0SOY20O318

Targets

P48740MASP1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with OMS906, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account